DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Premature Ejaculation - Pipeline Review, H1 2016" report to their offering.
This report provides comprehensive information on the therapeutic development for Premature Ejaculation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Premature Ejaculation and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
- Premature Ejaculation Overview
- Therapeutics Development
- Pipeline Products for Premature Ejaculation - Overview
- Pipeline Products for Premature Ejaculation - Comparative Analysis
- Premature Ejaculation - Therapeutics under Development by Companies
- Premature Ejaculation - Therapeutics under Investigation by Universities/Institutes
- Premature Ejaculation Products Glance
- Late Stage Products
- Clinical Stage Products
- Early Stage Products
- Premature Ejaculation - Products under Development by Companies
- Premature Ejaculation - Products under Investigation by Universities/Institutes
- Premature Ejaculation - Companies Involved in Therapeutics Development
- Allergan Plc
- Aytu BioScience, Inc.
- Ixchelsis Limited
- NeuroHealing Pharmaceuticals Inc.
- Plethora Solutions Holdings Plc
- SK Chemicals Co., Ltd.
For more information visit http://www.researchandmarkets.com/research/94qbf6/premature